CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for ...
Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992 ; 40 : 259 –263.Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J ...
Increasing evidence supports a role for small extracellular vesicles (sEV, including exosomes) in Diffuse Large B-cell lymphoma (DLBCL) progression and resistance to treatment. CD20 and PD-L1 are found on DLBCL-derived sEV, but little is known about thei
Donor-derived cell-free DNA as a diagnostic marker for kidney-allograft rejection: a systematic review and meta-analysis Biomol. Biomed. (2024), 10.17305/bb.2024.10049 Google Scholar [34] Advisory Committee on Immunization Practices https://www.cdc.gov/vaccines/acip/index.html (2024) (accessed ...
After exclusion of unwanted cell types by lineage marker expression, the relevant populations were identified as shown in the gating strategy of each figure. For each population of interest, we analyzed the median fluorescence intensity (MFI) of the ENPP1 staining and the frequency of ENPP1-...
The presence of T cells that are dimly positive for the B cell marker CD20 is well-established in autoimmunity and correlates with disease severity in various diseases. Further, we previously identified that the level of CD20-positive T cells was three–
The human CD19 antigen (Figure 1(a)) is a 95 kD glycosylated type I transmembrane protein on the surface of B lymphocytes, which is the earliest discovered surface marker of B-cell lineage. CD19 CAR T-cell therapy is the most advanced and has achieved impressive achievement in the ...
Recently, it was shown that highly effective anti-CD20 therapies used for MS patients not only deplete CD20+ B cells, but also a small subset of T cells expressing CD20 surface marker (CD3+CD20+ T cells). Here we demonstrated that, in progressive MS patients, CD3+CD20+ T cells share the...
Recently we investigated a candidate of CICs of lymphoplasmacytic lymphoma (LPL), which is positive for both B-cell marker CD20 and plasma-cell marker CD138. We reported that the subpopulation of CD20− CD138− phenotype, in which both markers were negative was a candidate of CICs in ...
CD20 was first identified as a B-cell specific marker in 1980 [13], which was highly expressed on more than 80% of B-cell lymphomas but not on stem cells, pro-B cells, normal plasma cells, or other normal tissues [14].The CD20 gene, namely MS4A1 gene, is located on chromosome 11...